Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent Gliosarcoma · Recurrent Supratentorial Glioblastoma · Supratentorial Gliosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

M D Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Shiao-Pei S. Weathers, MD) · sweathers@mdanderson.org · 713-792-2883
Contact: Principal Investigator (Shiao-Pei S. Weathers, MD)

Study leads

Shiao-Pei S Weathers, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Glioblastoma · Glioblastoma, IDH-Wildtype · Gliosarcoma

Abroad (travel likely)RecruitingPHASE1

Los Angeles, United States · New York, United States

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

Recurrent High Grade Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma

Abroad (travel likely)RecruitingPHASE1

Omaha, United States

Study of Pembrolizumab and M032 (NSC 733972)

Glioblastoma Multiforme · Anaplastic Astrocytoma · Gliosarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

IDH1 wt Allele · Recurrent Anaplastic Astrocytoma · Recurrent Glioblastoma

Abroad (travel likely)RecruitingPHASE1

Houston, United States